Oppenheimer lowered the firm’s price target on Gilead (GILD) to $125 from $132 and keeps an Outperform rating on the shares. The firm notes that Gilead reported lighter than anticipated Q1 revenues on Thursday. While Oppenheimer says it “knew HIV would take a hit,” the firm notes TRODELVY’s miss was more surprising.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $135 from $130 at Morgan Stanley
- Gilead Sciences: Strong Core Business and Growth Potential Amid Valuation Opportunities
- Gilead Sciences: Hold Rating Amid Mixed Performance and Future Opportunities
- Gilead Sciences: Strong Growth Prospects and Strategic Positioning Support Buy Rating
- Gilead Sciences Reports Strong Start to 2025